{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:15:06Z","timestamp":1753892106756,"version":"3.41.2"},"reference-count":36,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,10,18]],"date-time":"2021-10-18T00:00:00Z","timestamp":1634515200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p><jats:bold>Background:<\/jats:bold> The long-term effects of statin use on rehospitalization due to ischemic stroke (reHospIS) in hyperlipidemic patients are still unknown. Therefore, we aimed to assess the long-term risks of reHospIS for hyperlipidemic patients who were taking statins and nonstatin lipid-lowering medicines on a regular basis.<\/jats:p><jats:p><jats:bold>Methods and Materials:<\/jats:bold> The National Health Insurance Research Database in Taiwan was used to conduct a 6-year cohort study of patients &amp;gt;45\u00a0years old (<jats:italic>n<\/jats:italic> = 9,098) who were newly diagnosed with hyperlipidemia and hospitalized for the first or second time due to ischemic stroke (IS). The risk of reHospIS was assessed using Cox proportional hazards regression model.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> Nonstatin lipid-lowering medicines regular users were associated with a higher risk of reHospIS compared to stains users (hazard ratio, HR = 1.29\u20131.39, <jats:italic>p<\/jats:italic> &amp;lt; 0.05). Rosuvastatin was the most preferred lipid-lowering medicine with lower HRs of reHospIS in hyperlipidemic patients whether they developed diabetes or not. Bezafibrate regular users of hyperlipidemic patients developing diabetes (HR = 2.15, <jats:italic>p<\/jats:italic> &amp;lt; 0.01) had nearly 50% lower reHospIS risks than those without diabetes (HR = 4.27, <jats:italic>p<\/jats:italic> &amp;lt; 0.05). Age, gender, drug dosage, comorbidities of diabetes and heart failure (HF), and characteristics of the first hospitalization due to IS were all adjusted in models. Moreover, increasing trends of HRs of reHospIS were observed from Rosuvastatin, nonstatin lipid-lowering medicines, Lovastatin, and Gemfibrozil to Bezafibrate users.<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> Statins were associated with long-term secondary prevention of reHospIS for hyperlipidemic patients. Rosuvastatin seemed to have the best protective effects. On the other hand, Bezafibrate appears to be beneficial for hyperlipidemic patients developing diabetes. Further research into the combination treatment of statin and nonstatin lipid-lowering medicines in hyperlipidemic patients developing diabetes is warranted.<\/jats:p>","DOI":"10.3389\/fphar.2021.741094","type":"journal-article","created":{"date-parts":[[2021,10,19]],"date-time":"2021-10-19T17:59:10Z","timestamp":1634666350000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Long-Term Use of Statins Lowering the Risk of Rehospitalization Caused by Ischemic Stroke Among Middle-Aged Hyperlipidemic Patients: A Population-Based Study"],"prefix":"10.3389","volume":"12","author":[{"given":"Jiu-Haw","family":"Yin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giia-Sheun","family":"Peng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kang-Hua","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chi-Ming","family":"Chu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wu-Chien","family":"Chien","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li-Ting","family":"Kao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chia-Chao","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chih-Wei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen-Chiuan","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei-Zhi","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi-Syuan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hung-Che","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu-Tien","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2021,10,18]]},"reference":[{"key":"B1","unstructured":"edition_ICD-9-CM 2001 Edition and ICD-10-CM\/PCS Corresponding Files. 2021\n            AdministrationN. H. I.\n          2014"},{"key":"B2","doi-asserted-by":"publisher","first-page":"875907","DOI":"10.1155\/2014\/875907","article-title":"Comparison of Low-Dose Rosuvastatin with Atorvastatin in Lipid-Lowering Efficacy and Safety in a High-Risk Pakistani Cohort: an Open-Label Randomized Trial","volume":"2014","author":"Arshad","year":"2014","journal-title":"J. Lipids"},{"key":"B3","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1038\/jcbfm.2013.38","article-title":"Hyperlipidemia Disrupts Cerebrovascular Reflexes and Worsens Ischemic Perfusion Defect","volume":"33","author":"Ayata","year":"2013","journal-title":"J. Cereb. Blood Flow Metab."},{"key":"B4","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/s0195-668x(02)00419-0","article-title":"Statin Effects beyond Lipid Lowering-Aare They Clinically Relevant","volume":"24","author":"Bonetti","year":"2003","journal-title":"Eur. Heart J."},{"key":"B5","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1007\/s11940-019-0563-4","article-title":"Statins in Ischemic Stroke Prevention: What Have We Learned in the Post-SPARCL (The Stroke Prevention by Aggressive Reduction in Cholesterol Levels) Decade","volume":"21","author":"Castilla-Guerra","year":"2019","journal-title":"Curr. Treat. Options. Neurol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1756286420920078","DOI":"10.1177\/1756286420920078","article-title":"Low-dose Statin Pretreatment Improves Function and Prognosis of Recurrent Ischemic Stroke Patients","volume":"13","author":"Cui","year":"2020","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"B7","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/s0021-9150(99)00331-7","article-title":"The Effect of Vitamin E, Probucol, and Lovastatin on Oxidative Status and Aortic Fatty Lesions in Hyperlipidemic-Diabetic Hamsters","volume":"149","author":"El-Swefy","year":"2000","journal-title":"Atherosclerosis"},{"key":"B8","doi-asserted-by":"publisher","first-page":"3J","DOI":"10.1016\/s0002-9149(98)00423-8","article-title":"Current and Future Treatment of Hyperlipidemia: the Role of Statins","volume":"82","author":"Farnier","year":"1998","journal-title":"Am. J. Cardiol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1678","DOI":"10.1212\/WNL.0b013e3182575142","article-title":"Inpatient Statin Use Predicts Improved Ischemic Stroke Discharge Disposition","volume":"78","author":"Flint","year":"2012","journal-title":"Neurology"},{"key":"B10","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1161\/STROKEAHA.111.627729","article-title":"Statin Use during Ischemic Stroke Hospitalization Is Strongly Associated with Improved Poststroke Survival","volume":"43","author":"Flint","year":"2012","journal-title":"Stroke"},{"key":"B11","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.molmet.2016.12.007","article-title":"Bezafibrate Ameliorates Diabetes via Reduced Steatosis and Improved Hepatic Insulin Sensitivity in Diabetic TallyHo Mice","volume":"6","author":"Franko","year":"2017","journal-title":"Mol. Metab."},{"key":"B12","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1590\/0004-282X20190172","article-title":"Association between Statin Use and Mortality Risks during the Acute Phase of Ischemic Stroke in Patients Admitted to an Intensive Care Unit","volume":"78","author":"Furlan","year":"2020","journal-title":"Arq Neuropsiquiatr"},{"key":"B13","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1212\/WNL.0000000000001814","article-title":"Statin Treatment Reduces the Risk of Poststroke Seizures","volume":"85","author":"Guo","year":"2015","journal-title":"Neurology"},{"key":"B14","doi-asserted-by":"publisher","first-page":"349","DOI":"10.2147\/CLEP.S196293","article-title":"Taiwan's National Health Insurance Research Database: Past and Future","volume":"11","author":"Hsieh","year":"2019","journal-title":"Clin. Epidemiol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1097\/JCP.0000000000000051","article-title":"A Prospective Study of Statin Use and Poststroke Depression","volume":"34","author":"Kim","year":"2014","journal-title":"J. Clin. Psychopharmacol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1159\/000342302","article-title":"Low Cholesterol, Statins and Outcomes in Patients with First-Ever Acute Ischemic Stroke","volume":"34","author":"Koton","year":"2012","journal-title":"Cerebrovasc. Dis."},{"key":"B17","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1089\/jmf.2020.0029","article-title":"Effect of Berberine Plus Bezafibrate Administration on the Lipid Profile of Patients with Mixed Dyslipidemia: A Pilot Clinical Trial","volume":"24","author":"Le\u00f3n-Mart\u00ednez","year":"2021","journal-title":"J. Med. Food"},{"key":"B18","doi-asserted-by":"publisher","first-page":"926","DOI":"10.3389\/fphar.2018.00926","article-title":"Beneficial Role of Rosuvastatin in Blood-Brain Barrier Damage Following Experimental Ischemic Stroke","volume":"9","author":"Lu","year":"2018","journal-title":"Front. Pharmacol."},{"key":"B19","unstructured":"Hyperlipidemia\n            HillM. F.\n            BordoniB.\n          2021"},{"key":"B20","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1177\/1747493019873594","article-title":"Statin-based Therapy for Primary and Secondary Prevention of Ischemic Stroke: A Meta-Analysis and Critical Overview","volume":"15","author":"Milionis","year":"2020","journal-title":"Int. J. Stroke"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.15277\/bjd.2018.180","article-title":"Cardiovascular Outcomes Trials with Non-statin Lipid-Lowering Drugs in Diabetes","volume":"18","author":"Naeem","year":"2018","journal-title":"Br. J. Diabetes"},{"volume-title":"Taiwan Diabetes Yearbook 2019","year":"2019","key":"B22"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1161\/CIRCULATIONAHA.115.016183","article-title":"Clinical Effectiveness of Statin Therapy after Ischemic Stroke: Primary Results from the Statin Therapeutic Area of the Patient-Centered Research into Outcomes Stroke Patients Prefer and Effectiveness Research (PROSPER) Study","volume":"132","author":"O'Brien","year":"2015","journal-title":"Circulation"},{"key":"B24","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1001\/jama.2020.7848","article-title":"Association of Statin Use with All-Cause and Cardiovascular Mortality in US Veterans 75 Years and Older","volume":"324","author":"Orkaby","year":"2020","journal-title":"JAMA"},{"key":"B25","doi-asserted-by":"publisher","first-page":"115","DOI":"10.5114\/aoms.2015.49216","article-title":"The Influence of Statin Therapy on Platelet Activity Markers in Hyperlipidemic Patients after Ischemic Stroke","volume":"11","author":"Pawelczyk","year":"2015","journal-title":"Arch. Med. Sci."},{"key":"B26","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1097\/MOL.0000000000000528","article-title":"Towards More Specific Treatment for Diabetic Dyslipidemia","volume":"29","author":"Rodriguez","year":"2018","journal-title":"Curr. Opin. Lipidol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1111\/j.1747-4949.2012.00864.x","article-title":"Reduced Risk of Poststroke Pneumonia in Thrombolyzed Stroke Patients with Continued Statin Treatment","volume":"10","author":"Scheitz","year":"2015","journal-title":"Int. J. Stroke"},{"key":"B28","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1007\/s00592-017-1089-4","article-title":"New Treatment Options for Lipid-Lowering Therapy in Subjects with Type 2 Diabetes","volume":"55","author":"Scicali","year":"2018","journal-title":"Acta Diabetol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.2174\/156802609789869628","article-title":"Dyslipidemia as a Risk Factor for Ischemic Stroke","volume":"9","author":"Tziomalos","year":"2009","journal-title":"Curr. Top. Med. Chem."},{"key":"B30","doi-asserted-by":"publisher","first-page":"104697","DOI":"10.1016\/j.jstrokecerebrovasdis.2020.104697","article-title":"Statin Pretreatment Might Be Associated with Decreased Myocardial Injury after Ischemic Stroke","volume":"29","author":"Wang","year":"2020","journal-title":"J. Stroke Cerebrovasc. Dis."},{"key":"B31","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1136\/heart.88.3.229","article-title":"Adherence to Statin Treatment and Readmission of Patients after Myocardial Infarction: a Six Year Follow up Study","volume":"88","author":"Wei","year":"2002","journal-title":"Heart"},{"key":"B32","unstructured":"Defined Daily Dose (DDD)2020"},{"key":"B33","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1177\/1747493016670175","article-title":"Hyperlipidemia Is Associated with Lower Risk of Poststroke Mortality Independent of Statin Use: A Population-Based Study","volume":"12","author":"Yeramaneni","year":"2017","journal-title":"Int. J. Stroke"},{"key":"B34","doi-asserted-by":"publisher","first-page":"2542","DOI":"10.18632\/aging.101931","article-title":"Aging and Ischemic Stroke","volume":"11","author":"Yousufuddin","year":"2019","journal-title":"Aging (Albany NY)"},{"key":"B35","doi-asserted-by":"publisher","first-page":"564","DOI":"10.2174\/1570159X12666140923210929","article-title":"The many Roles of Statins in Ischemic Stroke","volume":"12","author":"Zhao","year":"2014","journal-title":"Curr. Neuropharmacol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"311","DOI":"10.3233\/RNN-201012","article-title":"Prestroke Statin Use Enhances Collateralization in Acute Ischemic Stroke Patients","volume":"38","author":"Zhu","year":"2020","journal-title":"Restor Neurol. Neurosci."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2021.741094\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,19]],"date-time":"2021-10-19T18:00:12Z","timestamp":1634666412000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2021.741094\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,18]]},"references-count":36,"alternative-id":["10.3389\/fphar.2021.741094"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2021.741094","relation":{},"ISSN":["1663-9812"],"issn-type":[{"type":"electronic","value":"1663-9812"}],"subject":[],"published":{"date-parts":[[2021,10,18]]},"article-number":"741094"}}